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Abstract
Tar DNA Binding Protein-43 (TDP-43) is a principle component of inclusions in many cases of frontotemporal lobar
degeneration (FTLD-U) and amyotrophic lateral sclerosis (ALS). TDP-43 resides predominantly in the nucleus, but in affected
areas of ALS and FTLD-U central nervous system, TDP-43 is aberrantly processed and forms cytoplasmic inclusions. The
mechanisms governing TDP-43 inclusion formation are poorly understood. Increasing evidence indicates that TDP-43
regulates mRNA metabolism by interacting with mRNA binding proteins that are known to associate with RNA granules.
Here we show that TDP-43 can be induced to form inclusions in cell culture and that most TDP-43 inclusions co-localize with
SGs. SGs are cytoplasmic RNA granules that consist of mixed protein - RNA complexes. Under stressful conditions SGs are
generated by the reversible aggregation of prion-like proteins, such as TIA-1, to regulate mRNA metabolism and protein
translation. We also show that disease-linked mutations in TDP-43 increased TDP-43 inclusion formation in response to
stressful stimuli. Biochemical studies demonstrated that the increased TDP-43 inclusion formation is associated with
accumulation of TDP-43 detergent insoluble complexes. TDP-43 associates with SG by interacting with SG proteins, such as
TIA-1, via direct protein-protein interactions, as well as RNA-dependent interactions. The signaling pathway that regulates
SGs formation also modulates TDP-43 inclusion formation. We observed that inclusion formation mediated by WT or mutant
TDP-43 can be suppressed by treatment with translational inhibitors that suppress or reverse SG formation. Finally, using
Sudan black to quench endogenous autofluorescence, we also demonstrate that TDP-43 positive-inclusions in pathological
CNS tissue co-localize with multiple protein markers of stress granules, including TIA-1 and eIF3. These data provide support
for accumulating evidence that TDP-43 participates in the SG pathway.
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Introduction
TDP-43 is the principle protein component of inclusions in ALS
and ubiquitin positive frontotemporal lobar degeneration (FTLD-
U) [1]. Currently more than thirty mutations in TDP-43 have
been identified in familial and sporadic ALS [2,3]. Mutations in
TDP-43 are considered as a major cause of familial ALS. TDP-43
is a 414 amino acid nuclear protein encoded by the TARDBP
gene on chromosome 1. Although it is ubiquitously expressed in all
tissues, it highly expresses in the brain and kidney [4]. TDP-43 is
an mRNA binding protein that plays important functions in
regulating mRNA metabolism involved in several functions,
including transcriptional repression, exon skipping and RNA
splicing [5,6]. It contains two RNA binding domains and a glycine
rich domain at the C terminus. The two RNA recognition motifs
and the C terminal glycine-rich domains in the TAR-DNA appear
to be important for its interactions with nucleic acids [5,6]. TDP-
43 predominantly expresses in the nucleus where it exerts its
biological functions, but in pathological tissue TDP-43 is
aberrantly processed and forms inclusions in the cytoplasm. The
mislocalization of TDP-43 in the cytoplasm highlights important
gaps in our knowledge of TDP-43 biology.
mRNA binding proteins facilitate mRNA trafficking from the
nucleus to the cytoplasm as part of the biological machinery that
regulates mRNA metabolism, such as RNA decay and protein
translation. RNA decay is a constitutive process that occurs in
cytoplasmic compartments termed processing bodies (P-bodies).
However, under stressful conditions mRNA binding proteins con
solidate mRNA in cytoplasmic compartments, termed the stress
granules (SGs); this recruitment is mediated by multiple proteins,
including T-cell intracellular antigen 1 (TIA-1), RasGAP-associ-
ated endoribnuclease (G3BP), elongation initiation factor 3 (eIF3)
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and poly-A binding protein (PABP) [7]. SGs function in part to
triage RNA and sequester transcripts not needed for coping with
the stress [7]. The mechanism of SG formation is striking because
it results from the regulated, reversible aggregation process of
mRNA binding proteins with prion-like domains, such as TIA-1,
TIAR and G3BP[8].
TDP-43 inclusions isolated from brains of subjects with FTLD-
U contain full-length TDP-43 as well as C-terminal cleavage
fragments that are approximately 25 and 35 KD in size [1].
Recent studies with cell lines indicate that TDP-43 can form
cytoplasmic inclusions when expression is forced to the cytoplasm
by removal of the nuclear localization signal [9,10]. TDP-43
inclusions also occur upon apoptosis, possibly because the
caspase-generated cleavage fragments of TDP-43 have a strong
tendency to aggregate [9,11,12,13]. Increasing evidence suggests
that TDP-43 cytoplasmic inclusions observed in cell culture are
SGs [14,15], but the mechanisms by which TDP-43 might
associate with SG are unknown. In addition, also unknown are
questions such as whether SG biology contributes to ALS and
how disease-linked TDP-43 mutations might participate in this
process. We now report that TDP-43 co-localizes with SGs in
cells and in affected CNS tissue from patients with ALS or
FTLD-U. We also report that TDP-43 binds to TIA-1, an
intrinsic SG protein, which provides a potential mechanism for
association of TDP-43 with SGs in ALS and FTLD-U. In
additions, we report that disease-linked mutations in TDP-43
increase the formation of cytoplasmic TDP-43 inclusions that are
co-localized with SG markers.
Results
Over-expressed TDP-43 forms cytoplasmic inclusions that
co-localize with SG
To test whether inclusions would form in neuronal cells, human
BE-M17 neuroblastoma cells were transfected with WT TDP-43,
TDP-4386–414 or TDP-43216–414 constructs N-terminally tagged
with EGFP (Fig 1). The TDP-4386–414 and TDP-43216–414 deletion
constructs were designed to correlate with the TDP-43 cleavage
fragments of approximately 35 and 25 KD that are present in
brain of subjects with TDP-43 pathology [1,11]. Full length WT
TDP-43 predominently localized to the nucleus under basal
conditions with only 10% of the cells exhibiting TDP-43 inclusions
(Fig. 2A; Supplemental figure S1 shows an example of a cell with
some cytoplasmic TDP-43 inclusions). In contrast, about 30% of
the cells over-expressing TDP-4386-414formed abundant cyto-
plasmic inclusions under basal conditions (Fig. 2A). Cells
expressing the TDP-43216–414 construct also formed inclusions
(Fig. 2A), but the number of cells exhibiting fluorescence was
low, possibly due to cytotoxicity [11]. The inclusions were
predominantly cytoplasmic, but were also present in the nucleus
(Fig. 2A).
Many studies suggest that protein aggregation increases under
stressful conditions. To investigate TDP-43 aggregation under the
stressful conditions, cells were exposed to arsenite, an agent is
classically used to induce SGs [16,17,18]. Arsenite causes stress
through multiple mechanisms [19]. Arsenite directly induces
oxidative stress by reacting with oxygen in a reaction similar to the
Fenton reaction, and arsenite also uses up glutathione, which
causes further oxidative stress [19]. Metabolic responses to arsenite
include induction of heat shock proteins, stimulation of NFkB and
induction of glucose transporters; the latter change suggests that
arsenite might also simulate nutrient deprivation [19]. Each of
these changes is known to inhibit protein translation and induce
stress granule formation, which makes arsenite an excellent agent
for inducing stress granules. Upon exposure to arsenite (0.5 mM,
1 hr) WT TDP-43 remained largely nuclear, but a small amount
translocated to the cytoplasm where it formed inclusions (Fig. 2A,
right panels, arrows; quantification, Fig. 2B). Inclusion formation
was not specific to arsenite treatment because incubation in Hanks
balanced saline solution (1 hr, for nutrient deprivation) caused
formation of TDP-43 inclusions that also co-localized with the SG
marker, TIA-1 (Fig. 2C).
To determine whether the inclusions co-localized with SGs, we
co-labeled the cells with antibodies to SG markers, including TIA-
1, TIAR, eIF3 and poly-A binding protein (PABP). Double
labeling experiments indicated that inclusions composed of WT
TDP-43 co-localized with SG markers under arsenite-induced
conditions (Fig. 2A, B and 3B, arrows); TDP-43 inclusions also co-
localized with SG markers under basal conditions, but the fraction
of cells (,10%) exhibiting TDP-43 inclusions under basal
conditions. Co-localization with PABP is considered a strong
indication of coincident localization of mRNA. Inclusions
composed of TDP-4386–414 also co-localized with SG markers
under both basal and arsenite-induced conditions (Fig. 2A, B and
3A, arrows). Inclusions composed of TDP-43216–414 also co-
localized with SG markers (Fig. 2A, B), however the fraction of
TDP-43216–414 inclusions that co-labeled with the SG marker
TIA-1 was less than WT-TDP43 or the TDP-4386–414 fragment
(fig. 2B). Similar results were obtained when experiments were
performed using HEK 293 cells (data not shown).
We also explored the relationship between TDP-43 inclusions
and P-bodies, which are cytoplasmic protein-RNA complexes that
regulate mRNA turnover. We transfected BE-M17 cells with WT,
TDP-4386–414 or TDP-43216–414 fused to EGFP (designated as
Figure 1. TDP-43 constructs: Diagram showing the TDP-43 constructs used in this report. EGFP, Enhanced Green Fluorescent Protein;
RRM, RNA recognition motif; GRR, Glycine rich domain; NLS, nuclear localization signal; NES, nuclear export signal.
doi:10.1371/journal.pone.0013250.g001
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TDP-43::EGFP, and decapping protein 1a (Dcp1A) fused to RFP
(Dcp1a::mRFP), which labels P-bodies. After 24 hrs, the cells were
fixed, and examined by confocal microscopy. TDP-43 reactivity
for each of the constructs was largely localized in regions adjacent
to the Dcp1a/P-body reactivity, which is consistent with prior
reports indicating that P-bodies are distinct from SGs, but can
align adjacent to SGs and exchange some proteins and mRNA
(Fig. 3C, the arrows point to SGs, and triangle points to a P-body)
[7,20]. These data support the hypothesis that TDP-43 can
accumulate in cytoplasmic stress granules. However, this does not
preclude that TDP-43 can associate with P granules under some
conditions because many proteins, such as staufen, FMRP and
HuR (but not TIA-1 or eIF3) are present in P-bodies and stress
granules depending on the conditions [21,22].
Expression of TDP-43 did not affect total protein translation
under basal conditions, where protein translation is robust, or
following treatment with arsenite, where protein translation is
limited to stress response proteins (Fig. 4A). The experiment was
Figure 2. TDP-43 inclusions co-localize with SG proteins. A.) Cellular distribution of TDP-43::EGFP constructs in human neuroblastoma BE-M17
cells under basal conditions and after treatment with arsenite; the cells are co-labeled with anti-TIA-1 antibody (red, labeling SGs) and with DAPI
(blue, labeling nuclei). Basal conditions (left panel): WT TDP-43 (T-FL) typically shows diffuse nuclear expression, while TDP-43216–414 (T-216) and TDP-
4386–414 (T-86)::EGFP constructs form cytoplasmic and nuclear inclusions. TDP-43 reactivity co-localizes with RNA binding protein, TIA-1. Arsenite
treatment (right panel): Treatment with arsenite (0.5 mM, 1 hr) induces some TDP-43::EGFP to translocate to the cytoplasm where it forms inclusions
(arrows) that co-localize with TIA-1, indicating that the inclusions are SGs. The TDP-43216–414 and TDP-4386–414::EGFP constructs form inclusions in the
cytoplasm (arrows) and nucleus, but only inclusions generated by the TDP-4386–414 construct are increased by arsenite. The inclusions present in
arsenite treated cells co-localize with TIA-1. B.) Quantification of TDP-43 inclusions that co-localize with TDP-43 and TIA-1. C.) Incubation in Hanks
balanced salt solution for 1 hr induced formation of TDP-43 inclusions (arrows) that co-localized with TIA-1 positive inclusions. Transfected EGFP did
not form inclusions under the same conditions. Scale bar: 3 mm.
doi:10.1371/journal.pone.0013250.g002
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performed by transfecting HEK 293 cells with GFP or TDP-43
(WT). After 24 hrs, the cells were incubated in methionine free
medium for 1 hr, then medium containing azido-homoalanine
reagent was added to the cells for 15 min. The medium was
washed with complete medium, the cells were exposed to arsenite
for 45 min, then the lysates were harvested, labeled and
immunoblotted. The presence of TDP-43 did not elicit a
consistent change in protein translation. A representative protein
translation dose-response is shown in Figure 4A; although a small
amount of variation in translation was occasionally present
between gene constructs at any given concentration of arsenite,
there was no consistent effect of the transgenes upon repeat
experiments. Formation of the TDP-43216–414 inclusions stimulat-
ed caspase activity under basal conditions and increased caspase
activity after arsenite treatment (Fig. 4B), which is consistent with
earlier observations that the 25 KD fragment is particularly
cytotoxic [11].
Endogenously expressed TDP-43 also forms inclusions
that co-localize with SGs
Next we examined whether endogenous TDP-43 also formed
SG. Human BE-M17 neuroblastoma cells were exposed to arsenite
(0.5 mM, 1 hr), the cells were fixed and then immuno-labeled with
antibodies to TDP-43 or TIA-1. Most of the endogenous TDP-43
remained nuclear but a small amount translocated to the cytoplasm
where co-localization with TIA-1 was observed (Fig. 5, arrows). The
amount of cytoplasmic TDP-43 signal was low because labeling
only detected endogenous TDP-43, but the TDP-43 that was
present in the cytoplasm was largely in inclusions. Concurrent
treatment with cycloheximide (50 mg/ml, 1 hr) prevented inclusion
Figure 3. Co-localization of TDP-43 inclusions with SG markers. A.) Human neuroblastoma BE-M17 cells transfected with the TDP-4386–414 (T-
86::GFP) construct form cytoplasmic inclusions under basal conditions (arrows). The inclusions co-localize with endogenous SG markers including,
TIA-1, TIA-R and Poly A binding protein (PABP), identified by immunocytochemistry (ICC). B.) TDP-43 inclusions (WT= T-FL, TDP-43216–414 = T-216, TDP-
4386–414 = T-86, green) occurring after arsenite treatment also co-localize with eIF3 (red). C.) Double-labeling of TDP-43 and Dcp1a (a P-body protein
marker). BE-M17 cells were transfected with WT TDP-43::GFP= T-FL, TDP-4386–414::GFP = T-86 and TDP-43216–414 = T-216::GFP (green) and Dcp1a-mRFP
(red). The Dcp1a::mRFP labels P-bodies (triangle), which are adjacent to TDP-43 positive inclusions (arrow). The boxed area is shown in higher
magnification in the panels labeled ‘‘High Mag’’. Scale bar = 3 mm.
doi:10.1371/journal.pone.0013250.g003
Figure 4. Relationship of TDP-43 to translation and cell death. A.) Representative immunoblot showing the effects of TDP-43 on protein
translation. HEK-293 cells were transfected with GFP or TDP-43 (WT, TDP-4386–414 or TDP-43216–414). After 24 hrs they were treated 6 arsenite (0–
0.1 mM, 45 min), protein translation was assessed using click-chemistry labeling (15 min pulse). Arsenite treatment strongly inhibited translation of
most proteins. TDP-43 expression was not associated with any consistent changes in translation of proteins. B.) Induction of caspase activity upon
expression of TDP-43 constructs (WT= T-FL, TDP-43216–414 = T-216, TDP-4386–414 = T-86); control (Ctrl) refers to transfection with EGFP.
doi:10.1371/journal.pone.0013250.g004
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formation (Fig. 5). Thus, arsenite-treated cells form inclusions that
are positive for TDP-43 and TIA-1 under conditions of endogenous
expression or over-expression, and the inclusions are reversible with
cycloheximide or emetine. Together these data suggest that
inclusions composed of TDP-43 are bona fide SGs.
TDP-43 binds to TIA-1
To explore potential mechanisms by which TDP-43 associates
with SG, we examined whether TDP-43 binds TIA-1. HEK 293
cells were transfected with TDP-43 and/or TIA-1; co-transfection
with TIA-1 induces SGs (data not shown; 293 cells were used
because of the higher transfection efficiency). After 48 hrs the cells
were lysed and the proteins were immunoprecipitated, using
antibody to TIA-1. Cell lysates were treated with or without
RNase A before the immunoprecipitation to determine whether
any binding interactions were dependent on association with
mRNA, and the immunoprecipitated proteins were then im-
munoblotted with antibody to TDP-43. Co-association of TDP-43
and TIA-1 was readily apparent (fig. 6, upper panel, double stars).
A strong band corresponding to the molecular weight of TDP-
43::EGFP was evident in lanes co-transfected with TDP-
43::EGFP; however, association was not detected in cells
transfected with only TIA-1::RFP (fig. 6, upper panel, double
stars). Association between TDP-43 and TIA-1 was not abolished
by treatment with RNase, suggesting that the two proteins could
form a complex that was not dependent on RNA (fig. 6, lower
panel, double stars). Binding between endogenous TDP-43 and
TIA-1 was also apparent (fig. 6, upper panel, single star), but
appeared to be mediated by RNA because RNase treatment
eliminated reactivity (fig. 6, lower panel, single star). These data
suggest that TDP-43 can bind to TIA-1 at higher concentrations
of TDP-43, such as with over-expression, but that binding to TIA-
1 is not the predominant mechanism mediating association with
SGs under basal levels of TDP-43 expression.
Formation of cytoplasmic TDP-43 inclusions can be
prevented or reversed
A striking aspect of SG biology is that the inclusion formation is
regulated and reversible. SGs form rapidly in response to stress
and disperse upon removal of the stress. Formation of SG can be
prevented by concurrent treatment with agents that inhibit protein
translation but preserve polysomes, such as cycloheximide or
emetine [17]. In contrast, SG formation can be stimulated by
agents that inhibit protein translation by disrupt polysomes, such
Figure 5. Endogenous TDP-43 forms inclusions after treatment with arsenite (0.5 mM, 1 hr, arrows, BE-M17 cells), and the
inclusions are positive for TIA-1 (red). TDP-43 inclusions are suppressed by co-treatment with cycloheximide (50 mg/ml, 1 hr). Inclusions positive
for TDP-43 or TIA-1 are not evident under basal (Control) conditions. Scale bar: 10 mm.
doi:10.1371/journal.pone.0013250.g005
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as puromycin [17]. Inclusions containing the TDP-4386-414 were
responsive to SG modulators. Cycloheximide (20 mg/ml, 2 hr) and
emetine (20 mg/ml, 2 hr) dispersed the TDP-4386–414 inclusions
fully (Fig. 7A); the time course for inclusion dispersion was
sufficiently rapid to maintain TDP-43::EGFP expression despite
the translational inhibition as demonstrated by the maintenance of
GFP fluorescence (Fig. 7A). Conversely, puromycin (20 mg/ml,
3 hrs), which stimulates SG formation [17], increased formation of
TDP-4386–414 and full-length TDP-43 inclusions (Fig. 7A).
Formation of inclusions from TDP-43216–414was not very
responsive to treatment with cycloheximide, emetine or puromy-
cin (Fig. 7A), which is consistent with the observation that the
inclusions composed of TDP-43216–414 only partly co-localized
with stress granule markers (Fig. 2B).
Because TDP-43 is largely nuclear under basal conditions, we
tested whether translocation was required for regulation of
inclusion formation. K82/84A TDP-43 lacking a nuclear import
signal (Fig. 1) localized to the cytoplasm and formed abundant
cytoplasmic inclusions (Fig. 7B), which suggests that elevated
cytoplasmic TDP-43 expression stimulates inclusion formation.
However, cytoplasmic retention is not sufficient to maintain
inclusion formation, because the inclusions can be dispersed by
transient treatment with cycloheximide (Fig. 7B).
RNA binding domains are necessary for inclusion
formation
To investigate the role of the RNA binding domains, we deleted
one or both RNA binding domains and examined TDP-43
inclusion formation (Fig. 1). Constructs lacking the first RNA
binding domain (TDP-43DRRM1) or both binding domains
(TDP-43DRRM1/2) did not form inclusions under basal
conditions (Fig. 7C). Interestingly, both TDP-43DRRM1 and
TDP-43DRRM1/2 did form small cytoplasmic inclusions after
arsenite treatment (0.5 mM, 1 hr) (Fig. 7C). The stress-induced
inclusions co-localized with TIA-1 and were prevented by
concurrent treatment with cycloheximide (20 mg/ml, Fig. 7C).
These data suggest that the RNA binding domains can modify
inclusion formation under oxidative conditions.
Knockdown of TDP-43 does not inhibit SG formation
We proceeded to use knockdown experiments to examine
whether TDP-43 expression is required for SG formation. In order
to characterize knockdown by shRNA constructs, we used
HEK293 cells, which have a sufficiently high transfection
efficiency to quantify the degree of knockdown by immunoblot
(Supplemental Fig. S2A). Next, we knocked down TDP-43 using
Figure 6. Co-immunoprecipitation of TDP-43 and TIA-1. HEK 293 cells were transfected with TDP-43 (WT, K82/84A or A315T) and TIA-1. The
K82/84A TDP-43 construct has had the nuclear localization signal removed (this construct is used again in figure 7B), and the A315T TDP-43 construct
contains a mutation associated with familial ALS (this construct is used again in figure 8). The lysates were treated with RNase A (50 mg/ml) for 30 min
at 37uC. Immunoprecipitated was performed with antibody to TIA-1, and the immunoblots were probed with antibody to TDP-43. Left upper panel:
Abundant reactivity corresponding to the TDP-43::EGFP constructs(double star) was evident in lanes co-transfected TIA-1 with TDP-43::EGFP. A
weaker band at 43 KD (single star) was also evident, suggesting association between TIA-1 and endogenous TDP-43. Finally, a higher molecular
weight band, approximately consistent with the expected size of a TDP-43::EGFP dimer (,140 KD) was also evident in the lane corresponding to
A315T TDP-43 (triple star). Left lower panel: Following treatment with RNase A, binding to TDP-43 remained, although it was decreased (double
stars). Treatment with RNase A abolished binding between TIA-1 and endogenous TDP-43 (single star), and decreased binding to the upper band
(triple star), which presumably corresponds to the TDP-43::EGFP dimer. Right upper panel: Negative controls showing the specificity of the
immunoprecipitation. Left lane: Lysate (30 mg) of transfected cells used for immunoprecipitation. Right lane: Immunoprecipitation using rabbit IgG
instead of anti-TIA-1 antibody. The immunoblot was performed with anti-TDP-43 antibody.
doi:10.1371/journal.pone.0013250.g006
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these shRNA constructs, and identified transfected cells by co-
transfection with GFP. After 24 hrs, the cells were treated with
arsenite (0.5 mM, 1 hr), labeled with antibody to eIF3, and the
number of cells that showed labeling for GFP and eIF3 was
counted. Knockdown of TDP-43 did not alter the number of cells
positive for stress granules (Supplemental Fig. S2B). These data
suggest that TDP-43 does not modulate gross SG formation, but
we cannot rule out that modulation might be able to be detected
with a more sensitive assay or that TDP-43 modifies the RNA
composition of SGs.
Disease-linked mutations enhance cytoplasmic
translocation and SG formation
The strong link between TDP-43 and SG biology prompted us
to examine whether disease-linked mutations in TDP-43 also
enhance formation of inclusions through processes linked to SGs.
EGFP-tagged TDP-43 (WT, G294A, A315T, Q331K, Q343R)
were transfected into BE-M17 cells, and inclusion formation was
examined after treatment with arsenite (0.5 mM, 1 hr) in the
presence or absence of cycloheximide (50 mg/ml, 1 hr, Fig. 8).
The mutations induced small increases in TDP-43 inclusion
formation under basal conditions (Fig. 8B and Supplemental Fig.
S3). Arsenite treatment was associated with more inclusion
formation for mutant TDP-43 constructs than for WT TDP-43
(Fig. 8A & B and Supplemental Fig. S3). The inclusions that
formed in response to arsenite fully co-localized with TIA-1,
suggesting that inclusion formed by mutant TDP-43 were also SGs
(Fig. 8A and Supplemental Fig. S3). In each case, formation of
inclusions composed of mutant TDP-43 constructs was reversed by
cylcoheximide (10 mg/ml, 1 hr, Fig. 8A & B). Importantly, each of
the mutations also showed a striking decrease in nuclear
localization in response to arsenite treatment, suggesting that the
mutations increased the degree of nuclear export (Fig. 8A & B).
The enhanced stress-induced cytoplasmic localization associated
with these mutants might contribute to their strong tendency to
form inclusions. These data suggest that enhancement of
inclusions with properties resembling SGs is a common feature
of TDP-43 mutations associated with ALS.
Next we investigated the relationship between inclusion
formation and solubility because prior studies suggest that TDP-
43 forms insoluble inclusions [10,12]. HEK 293 cells were
transfected with EGFP or TDP-43 (WT, A315T or Q343R),
grown 48 hrs, incubated 60.5 mM arsenite, 1 hr, and fraction-
ated into detergent soluble and insoluble fractions. Each
fractionation was then immunoblotted. Arsenite treatment in-
creased the amount of insoluble endogenous TDP-43 (Fig. 9, lower
panel, CT and EGFP lanes, single star) and transfected TDP-
43::EGFP (Fig. 9, lower panel, TDP-43::EGFP, double star).
Disease-linked mutant TDP-43 constructs were associated with
more increased amounts of total TDP-43 in the insoluble fraction
than the WT TDP-43 (Fig. 9, A315T, Q343R, double star, lower
panel). Compared to the WT TDP-43, the mutant TDP-43
constructs also showed increased levels of high-molecular weight
species, which were present in the insoluble fraction (Fig. 9, lower
panels, triple stars). Interestingly, the amount of endogenous TDP-
43 present in the insoluble fraction in cells expressing mutant
Figure 7. Regulation of TDP-43 inclusion formation by stress granule modulators. A) The translational inhibitors cycloheximide (50 mg/ml,
1 hr) or emetine (20 mg/ml, 1 hr) disperse inclusions formed by WT-TDP-43::EGFP (T-FL) TDP-4386–414::EGFP (T-86), while puromycin (20 mg/ml, 3 hrs)
increases formation of TDP-4386–414::EGFP inclusions formation. Puromycin also induces formation of cytoplasmic inclusions formed by WT and TDP-
4386–414::EGFP (arrows). However, puromycin does not change the abundance of TDP-43216–414::EGFP (T-216) inclusions. B) TDP-43::EGFP lacking the
nuclear localization signal (TDP-43 K82/84A) forms abundant cytoplasmic inclusions that co-localize with TIA-1 (anti-TIA-1 antibody, red) after arsenite
treatment. The inclusions are dispersed by co-treatment with cycloheximide (50 mg/ml, 1 hr). Quantification is shown in the bar graph to the right. C.)
Cells were transfected with the TDP-43 DRRM1 and DRRM1/2 constructs (N-terminal EGFP tag). After 24 hrs the cells were subjected to two
conditions: arsenite (0.5 mM, 1 hr) or arsenite plus cycloheximide (50 mg/ml, 1 hr). The cells were then fixed, and immunocytochemistry was
performed TDP-43 inclusions co-localized with TIA-1. Arrows point to representative inclusions showing co-localization of TDP-43 and TIA-1.
Cytoplasmic TDP-43 inclusion formation was not apparent under basal conditions, however under conditions of arsenite exposure both constructs
formed inclusions that co-localized with TIA-1 and were cycloheximide reversible. Quantification is shown in the bar graphs to the right. Scale bar:
10 mm.
doi:10.1371/journal.pone.0013250.g007
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TDP-43 was also increased, suggesting recruitment of endogenous
TDP-43 to SGs (Fig. 9, lower panel, single star).
Disease-linked mutations enhance toxicity
Previous studies suggest that Q331K TDP-43 expression causes
cell death [2]. We hypothesized that the deleterious effects of
mutant TDP-43 expression might be linked to SG formation. To
investigate the regulation of TDP-43 toxicity, we transfected HEK
293 cells with EGFP or TDP-43 (WT, G294K or Q331K) and
measured toxicity using caspase 3/7 activity as a readout. We
observed that cells expressing TDP-43 constructs showed elevated
caspase 3/7 activity compared to EGFP under basal conditions
(Fig. 10A). To investigate the effects of TDP-43 on cell death we
examined cells expressing TDP-43 constructs under basal
conditions or under conditions in which arsenite induced cell
death over 12 hrs. A chronic (12 hrs) stress design was used to
facilitate observation of the moderate effects of transgenes, such as
TDP-43, on cell death processes. Disease-linked mutations in
Figure 8. ALS-linked TDP-43 mutations increase aggregation in response to arsenite-induced stress. A) Representative pictures of
human neuroblastoma BE-M17 cells transfected with WT, Q331K or Q343R TDP-43::EGFP. The Q331K and Q343R TDP-43::EGFP constructs produce
more inclusions (arrows) than WT construct after treatment with arsenite (0.5 mM, 1 hr). However, co-treatment of arsenite and cycloheximide (CHX,
50 mg/ml, 1 hr) prevents formation of inclusions. B) Quantification of cytoplasmic inclusion formation for EGFP and TDP-43-EGFP constructs (WT,
G294A, A315T, Q331K and Q343R) under different conditions (basal, arsenite and arsenite + cycloheximide). 15 fields were counted per condition.
Scale bar = 8 mm.
doi:10.1371/journal.pone.0013250.g008
Figure 9. Disease-linked TDP-43 mutations are associated with increased levels of insoluble protein aggregates. HEK 293 cells were
transfected with TDP-43 (WT, A315T or Q343R). After 48 hrs, the cells were treated 6 arsenite (0.5 mM, 1 hr), separated into soluble and insoluble
fractions, and immunoblotted. Upper panel: Soluble fraction. Lower panel: Insoluble fraction. Several different species of TDP-43 could be observed
including bands putatively corresponding to endogenous TDP-43 (single star), TDP-43::EGFP (double star) and dimeric TDP-43::EGFP (triple star).
Mutations were associated with increased levels of insoluble TDP-43 and increased levels of TDP-43 breakdown products (bands under the TDP-
43::EGFP) after arsenite treatment.
doi:10.1371/journal.pone.0013250.g009
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TDP-43 enhanced toxicity over that with WT TDP-43 after
treatment with arsenite (50 mM, 12 hrs, Fig. 10B). Imaging of the
cells under these conditions showed formation of TDP-43 positive
inclusions (Fig. 10C). Assessment of toxicity depended on the
particular assay utilized. For instance, disease-linked mutations in
TDP-43 showed greater toxicity under basal conditions than WT
TDP-43 with the LDH assay (Fig. 10B). The quantitative
differences between the LDH and caspase assays might reflect
differential thresholds for the LDH-release or caspase 3/7
activation, or differential signaling for necrosis (LDH assay) versus
apoptosis (caspase 3/7 assay). Despite some quantitative differ-
ences between different assays, the combined results provide
evidence that disease-linked TDP-43 mutations increase cell death
processes and SG formation.
TDP-43 inclusions in brain tissue from ALS and FTLD-U
donors co-localize with SG markers
Finally we examined whether TDP-43 pathology present in
ALS and FTLD-U cases were associated with SG markers.
Immunocytochemistry was performed on cases of ALS and
FTLD-U using antibodies to TDP-43 and SG markers, including
eIF3 and TIA-1. Sudan black was used to remove endogenous
autofluorescence due to lipofuscin (Fig. 11A); this method greatly
increased the ability to distinguish between fluorescence related to
the antibody signal and fluorescence caused by lipofuscin. Using
sudan black to remove autofluorescence, we were able to readily
visualize TDP-43 positive inclusions that showed co-labeling with
these SG markers in ALS spinal cord tissue and FTLD-U brain
(Fig. 11B & C). We also observed co-localization between
phospho-TDP-43 inclusions and eIF3 or TIA-1 (Fig. 11D). The
specificity of eIF3 staining was tested by immuno-absorption; pre-
absorption of TDP-43 antibodies with the antigenic peptide
eliminated all reactivity, indicating the specificity of the antibody
(Fig. 11E). The absence of reactivity following pre-absorption also
demonstrated that labeling of SG markers was not due to the
artifact of ‘‘bleed-through’’ from the green channel. No co-labeling
was observed with antibody to a different class of RNA-binding
protein, the P-body marker anti-Dcp1 (data not shown). In
addition, a prior study by Trojanowski and colleagues showed no
co-localization of TDP-43 with other RNA binding proteins [23].
Thus inclusions containing TDP-43 in the FTLD-U brain and
ALS spinal cord also contain SG proteins, which is consistent with
a hypothesis that SG biology is intimately linked to the
mechanisms underlying TDP-43 inclusion formation.
Discussion
Increasing evidence links RNA binding proteins to CNS
diseases. Mutations in other putative RNA binding proteins, such
as FUS, ataxin-2, SMN and FMRP, are associated with familial
ALS, spinocerebellar ataxia, spinal muscular atrophy and fragile X
syndrome, respectively [24,25]. The relationship between SGs and
neurodegenerative diseases has been suggested by previous
experiments demonstrating that PrP, SMN and huntingtin co-
localize with SG proteins in inclusions [26,27,28]. In addition,
SMN and ataxin-2 both regulate SGs [20,27]. In the current
study, we demonstrate that TDP-43 also co-localizes with SG
markers. We demonstrate that mutations in TDP-43 associated
with familial disease enhance inclusion formation in response to
stress, and also increase cell death. Inclusion formation could be
induced by multiple different types of stresses, including arsenite,
nutrient deprivation or puromycin. We demonstrate that TDP-43
inclusions are also associated with insoluble protein aggregates.
Finally, we show that TDP-43 inclusions in brains of subjects with
ALS and FTLD-U co-localize with SG markers. These data
suggest that TDP-43 can be added to this group of disease-related
proteins whose biology is intimately linked with SGs.
TDP-43 is an intrinsically aggregation prone protein [29].
Structural changes in TDP-43 can increase levels of TDP-43 in the
cytoplasm, and these changes appear to stimulate formation of
cytoplasmic inclusion. For instance, deletion of the nuclear
localization signal in TDP-43 forces expression of TDP-43 to
the cytoplasm and causes a concomitant increase in inclusion
formation [10]. Cleavage of TDP-43 also produces fragments that
exhibit exclusively cytoplasmic localization and a concomitant
increase in formation of cytoplasmic inclusions [9,12]. The A90V
mutation increases cytoplasmic localization of TDP-43 and is
associated with a corresponding increase in cytoplasmic inclusion
formation [30]. Expressing TDP-43 in vivo also appears to promote
inclusion formation. Over-expressing WT or mutant TDP-43 in
Figure 10. Quantification of toxicity. A) Disease-linked mutations in TDP-43 increase caspase 3/7 activity after arsenite treatment. HEK 293 cells
were transfected with EGFP, or TDP43 (WT, Q331K or Q343R). After 48 hrs the cells were treated 650 mM arsenite, 12 hrs later caspase 3/7 activity
was assayed under each condition. Results are shown normalized to EGFP transfected cells under basal conditions. B) BE-M17 cells were transfected
with EGFP, or TDP43 (WT, G294A or Q331K). LDH release was measured after 48 hrs and normalized to total LDH and transfection efficiency. Baseline
toxicity was set as the EGFP transfected neurons. Transfection with TDP-43 (WT, G294A or Q331K) increased LDH release, with G294A and Q331K TDP-
43 causing significantly more release than WT TDP-43 (N= 6 measurements per group). C.) Induction of TDP-43 inclusions by arsenite (50 mM) at
12 hrs.
doi:10.1371/journal.pone.0013250.g010
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Figure 11. Co-localization of TDP-43 inclusions with SG markers (eIF3 and TIA-1) in ALS and FTLD-U brain. A) Treatment of human
cortical brain sections with Sudan black strongly reduced endogenous fluorescence from lipofuscin in the red and green channels (subject 14,
Table 1); Blue channel is DAPI staining. B) Co-localization of TIA-1 with TDP-43 in inclusions present in the spinal cord of a patient with ALS (Ctrl =
subject 5, ALS = subject 1, Table 1). The boxed area is shown in higher magnification in the panels labeled ‘‘High Mag’’. C) TDP-43 inclusions in the
frontal cortex of a patient with FTLD-U co-localizes with eIF3 (Ctrl = subject 16, FTLD = subject 11, Table 1). FTLD-U and ALS sections with TDP-43
inclusions showed co-localization with SG markers. D) Co-localization of phospho-TDP-43 and eIF3 reactivity in FTLD-U brain (subject 10, Table 1). E)
Controls for immunocytochemistry. Row 1: TDP-43 present in brain tissue from a patient without neurological disease shows predominantly nuclear
localization (subject 14, Table 1). Row 2: TDP-43 positive cytoplasmic inclusion in a patient with FTLD-U showing co-localization with eIF3 (subject 9,
Table 1). Rows 3 – 5: Demonstration of immunoabsorption with antigenic peptide, which eliminates staining by eIF3 (Control sample = neurological
normal, subject 14; FTLD = subject 9, Table 1. Scale bars: A, B, C, D= 10 mm, E = 3 mm.
doi:10.1371/journal.pone.0013250.g011
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mice produces neurodegeneration that is associated with inclusion
formation [31,32].
Our data indicate that TDP-43 can associate with TIA-1, a
primary SG protein, however association only occurs upon over-
expressing TDP-43. The conditions used to examine the
association were conditions in which SG are present because
over-expressing TIA-1 induces formation of SGs that include
TDP-43. Co-localization of TDP-43 with SG proteins could result
from direct binding to SG proteins such as TIA-1, TIAR or G3BP,
or via indirect binding mediated by mRNA. Treatment of the
TDP-43/TIA-1 complex with RNase eliminated binding of
endogenous TDP-43, but did not eliminate binding of over-
expressed TDP-43, which suggests that binding can occur, but is
concentration dependent. We also noted that TDP-43 constructs
showing enhanced inclusion formation also bound TIA-1 in a
manner that was resistant to RNase A treatment. Complexes of
RNA binding proteins often contain interactions dependent on
both protein-protein interactions and protein-RNA interactions.
For instance, prior studies of cystic fibrosis transmembrane
conductance regulator show that co-association can also occur as
part of protein-RNA complexes regulating splicing of genes
[5,33,34]. Thus, the interaction between TDP-43 and SGs is
likely to reflect a mixed mechanism involving both protein-protein
interactions, as well as protein-RNA interactions. The type of
interaction might depend on the particular species of TDP-43 and
on the conditions at the binding site.
We also observed that four different disease-linked mutations in
TDP-43 increase cytoplasmic translocation and formation of
cytoplasmic inclusions with stress. There was also a modest
increase in inclusion formation under basal conditions. Our
observation that disease-linked mutations increase cytoplasmic
localization concurs with observations by two different groups
[30,35]. The increased inclusion formation was evident using
optical methods (immunocytochemistry) as well as through
biochemical methods in which we observed that arsenite increased
the amount of detergent insoluble TDP-43 and that disease-related
mutations increased the tendency of TDP-43 to form detergent
insoluble complexes. The analysis in our study adds to these
studies by providing comparison of 4 different mutations in one
study, while the other two studies each examined a single familial
mutant construct [30,35]. These results suggest that enhanced
cytoplasmic translocation might be a general mechanism by which
mutations in TDP-43 stimulate inclusion formation. Whether the
enhanced cytoplasmic translocation is responsible for the neuro-
toxicity remains to be determined. Our preliminary studies of cell
death, using the LDH and caspase assays, suggest a correlation
between cytoplasmic translocation and cell death. Interestingly,
Barmada et al observed that cytoplasmic translocaton, but not
inclusion formation correlated with toxicity [35]. Proof of this
hypothesis requires an experimental paradigm that inhibits
cytoplasmic TDP-43 translocation without changing the levels of
TDP-43 (our current tools, cycloheximide and emetine modulate
translation).
Co-localization of TDP-43 with SG markers is a robust
observation that can be observed with multiple independent
markers. We observed co-localization using antibodies to eIF3,
TIA and PABP. These observations are consistent with those of
Colombrita et al, who also observed co-localization of TDP-43
with SGs [15]. The role of TDP-43 in SG biology remains to be
determined, because neither we nor Columbrita et al observed any
affect of TDP-43 on general RNA translation [15].
The relevance of the link between TDP-43 and SGs is
supported by our studies of brain tissue of subjects with ALS or
FTLD-U. We observed co-localization under conditions of
endogenous expression of TDP-43 and co-localization of TDP-
43 in brain tissues from subjects with ALS and FTLD-U. We used
antibodies to TIA-1 and eIF3, and validated our work by
demonstrating that pre-absorption of eIF3 or TIA-1 eliminated
the staining, which proves the specificity. Volkening and
colleagues also observed co-localization between TDP-43 and
the SG proteins, staufen and TIA-1; they noted that the stress
granules were more abundant in ALS tissues [36]. On the other
hand, Columbrita et al were able to observe co-localization in cell
culture under conditions of over-expression but not in brain tissue
[15]. An important difference between our study and that of
Colombrita appears to be the methods of detection. We optimized
methods to reduce background and maximize the specificity of
staining. These methods included use of glycine for antigen
retrieval and sudan black for reducing autofluorescence. Tissue
not treated with with Sudan black and glycine showed extensive
autofluorescence (Fig. 11A). This autofluorescence confounds
studies attempting to detect co-localization of antigens by
immunofluorescence by creating fluorescent signal that is not
due to the antibody reactivity. Neither of these methods were used
in the paper by Columbrita et al [15]. The absence of techniques
reducing autofluorescence (from lipofuscin) might have contribut-
ed to a high level of background autofluorescence and low specific
antibody fluorescence signal [15]. Both problems would interfere
with the ability to detect co-localization of TDP-43 with SG
markers [15]. In contrast, the co-localization that we observed was
robust and the pattern of staining was consistent in appearance
with that shown in other studies of TDP-43 aggregation using
colorimetric methods [1,37,38]. Use of colorimetric methods
obviate problems associated with autofluorescence, but provide
weaker assessment of co-localization [1,37,38]. As independent
studies investigate the relationship between TDP-43 inclusions and
SG protein in brain tissue, the results will become clearer. At the
present time, the data presented in this manuscript strongly
suggest that SG biology plays an important role in the
pathophysiology of TDP-43 in ALS and FTLD-U.
The suggested relationship between protein aggregation, TDP-
43 and SG biology is tempered by a studies in Drosophila in which
over-expression of TDP-43 leads to neurodegeneration without
any apparent TDP-43 aggregation [39]. In addition, recent studies
in transgenic mice showed neurodegeneration with only a small
amount of cytoplasmic phospho-TDP-43 reactivity [32,40,41].
Neither of the TDP-43 transgenic models have shown increased
degeneration associated with use of TDP-43 constructs containing
mutations associated with familial ALS. These results might
indicate that degeneration associated with TDP-43 is unrelated to
the cytosolic inclusion formation, however the dose-dependent
TDP-43 neurodegeneration observed might also reflect degener-
ation associated with over-expression of TDP-43, perhaps related
to the RNA directed biological function of the protein. Thus,
whether the apparent limited aggregation associated with
degeneration in these transgenic models reflects biology relevant
to the human disease remains to be determined. In this context,
the results from our experiments are notable for their ability to
highlight physiological and biochemical effects associated with
disease-linked mutations in TDP-43. Future study designs in
transgenic animals will need to discriminate between effects
associated with over-expression of TDP-43 and effects associated
with mutations linked to familial disease.
The importance of TDP-43 for SGs does not preclude a role in
other biological processes. TDP-43 has been shown to regulate
CFTR exon skipping and RNA processing [4,5,33]. TDP-43 also
appears to play a role in dendrites where it shows changes in
cellular localization that correlate with neuronal activity [21].
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Wang and colleagues observed that neuronal activity appeared to
stimulate association of TDP-43 with P-bodies, which are
structures associated with RNA processing [21]. We observed
that TDP-43 largely co-localized SGs, but a small amount of
reactivity did appear to co-localize with P-bodies, which raises the
possibility that TDP-43 might contribute to multiple different
RNA-linked functions.
The observation that TDP-43 binds TIA-1, co-localizes with
SGs and can be modulated by factors that regulate SG biology
suggests intriguing questions related to mechanisms of neurode-
generation. Protein aggregation is classically considered to occur
through random association of like proteins [42]. However,
inclusions present in disease commonly contain many different
types of proteins. Some of the associated proteins are heat shock
proteins and chaperones that might reflect the cellular response to
limit protein aggregation [43]. SG biology provides a mechanism
for bringing together proteins under conditions that are physio-
logically designed to promote aggregation. Nucleation of SG
proteins in response to stress brings together many proteins that
have a strong tendency to form insoluble aggregates as an intrinsic
aspect of their biology. Some proteins, such as TDP-43 with
disease-related mutations or C-terminal cleavage fragments, or
proteins with expanded polyglutamine repeat domains, such as
ataxin-2, have a particularly strong tendency to aggregate and
form protein aggregates that resist dispersion [20]. A recent study
by Gitler and colleagues demonstrated that ataxin-2 binds TDP-43
and expanded polyglutamine domains in ataxin-2 promote
formation of TDP-43 inclusions [44]. The group also identified
cases of ALS that were TDP-43 positive and associated with
expanded polyglutamine stretches in ataxin-2 [44]. SG proteins
might enhance inclusion formation related to these proteins as a
result of their mutual associations.
The biology of SGs also suggests novel approaches for
therapeutic intervention. SG nucleation occurs via reversible
protein aggregation mechanism that is based on prion domains
present in TIA-1, TIAR and G3BP [8]. Our results suggest that the
RNA binding domains in TDP-43 also contribute to the regulation
of inclusions formation. SG biology represents a compelling
example of the biological utility of prion-based protein aggregation.
Reversible aggregation has been noted in other systems, such as the
interaction of tau with CHIP [45,46]. We were able to use the
reversibility of SG inclusions to suppress or disperse inclusions
containing full length TDP-43, and disperse inclusions composed of
TDP-43 cleavage fragments. This finding is in agreement with the
studies by Colombrita et al [15]. The reversibility of SG biology
might also be used to combat FTLD-U or ALS. Achieving
therapeutic utility requires as strategy that could selectively inhibit
or reverse TDP-43 inclusion formation without impairing SG
biology generally, which would be toxic. As the mechanisms
underlying the reversible aggregation of SGs become understood,
use of SGmodulators, rather than full translational inhibitors, might
provide sufficient biochemical selectivity much like gamma-
secretase modulators can reduce Ab production without inhibiting
the general function of gamma-secretase [47].
Materials and Methods
Plasmids
All TDP-43 cDNAs were inserted into a pEGFP-C1 vector at
BamH1/XbaI sites. shRNA TDP-43 constructs were in the
pLK0.1-puro vector (Sigma). The Dcp1a and TIA-1 cDNAs were
inserted into a pRFP vector modified to express monomeric RFP,
provided by Paul Anderson (Dana Farber Cancer Institute) and
Roger Tsien (UCSD).
Transfection
DNA was mixed with lipofectamine (Invitrogen) at a ratio of
1 mg/2.5 ml. Most experiments were initiated 24 hrs after
transfection, unless otherwise indicated and performed as
described previously [48].
shRNA Knockdown
HEK-293FT cells were grown in Dulbecco’s Modified Eagle
Medium (DMEM) plus 10% fetal bovine serum and 1% penicillin/
streptomycin. For TDP-43, two small hairpin RNAs (shRNAs) were
used corresponding to the following TDP-43 domain (amino acids):
927-951 and 1260-1281 (Sigma-Aldrich, Entrez accession number
NM_007375). The negative control consisted of a shRNA construct
against TDP-43 (corresponding to amino acids 177–197) that was
shown to have no effect on transcript or protein levels. Knockdown
was performed by mixing 3 mg of shRNA/plasmid with 7.5 ml of
Lipofectamine 2000 (Invitrogen) in a final volume of 500 ml of Opti-
MEM serum-free medium. HEK-293FT or BE-M17 cells were
incubated for 6 hours, and then fetal bovine serum was added to the
medium to 10% by volume. Twenty-four hours post-transfection,
cells were harvested for Western blot analysis. Cells were lysed on
ice in 200 ml of RIPA lysis buffer (10 mM Tris, pH 7.4, 150 mM
NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS, and 0.1% sodium
deoxycholate) containing freshly added protease and phosphatase
inhibitors, then rotated for 30 min at 4uC. The lysates were then
centrifuged at 14,000 rpm for 10 min at 4uC, the supernatant was
retained and protein concentration obtained by BCA assay (Pierce).
Immunocytochemistry
Cells were grown on poly-L-lysine-coated cover slips and were
treated as described in the text. Following treatment, the cells were
then rinsed with PBS, fixed with 4% paraformaldehyde for
15 min, permeabilized for 15 min with 0.2% Triton-X100/PBS,
and blocked for 1 hour in PBS containing 5% donkey serum.
Primary antibodies used were: rabbit anti-TDP-43 (1:1000,
Proteintech Group, Inc), rabbit anti-TDP-43, C-terminus (aa
405-415; 1:1000, Cosmo Bio. Co., #TIP-TD-P09), goat poly-
clonal TIA-1 (1:300, Santa Cruz, sc-1751) or eIF3g (1:300, Santa
Cruz, sc-16377). Secondary antibodies were: Dylight 488
conjugated donkey anti-rabbit IgG and Dylight 549 conjugated
donkey anti-goat IgG (1:600, Jackson ImmunoResearch). Primary
antibodies were diluted in blocking solution incubated with each
coverslip for overnight at 4uC. Cells were then washed three times
with PBS and subsequently incubated in secondary antibody for
1 hr, covered from light. Cells were then washed three times with
PBS and mounted in Prolong-Gold anti-fade reagent with DAPI
(Invitrogen). For quantification, four areas of each cover slip were
selected, the number of transfected cells and the number of
transfected cells with cytoplasmic aggregates were counted, and
the ratio was determined. Each condition was analyzed in
triplicate, giving a total of 12 measurements per point.
Immunohistochemistry of human tissue
Tissue sections were deparaffinized and rehydrated, then
treated with 0.1 M glycine for 30 min. The sections were washed
465 min in PBS, and microwaved on high in citrate buffer for
10 min. The sections were blocked for 1 hr with 10% donkey
serum in 0.2% triton X-100/PBS. Incubation was performed with
primary antibodies (described above) overnight in 5% donkey
serum/PBS. The sections were then washed 465 min, and
incubated in secondary anti-goat IgG (1:600, as above) for 1 hr,
washed 4610 min in PBS/0.02% Tween; the third wash included
DAPI (1 mg/ml). Background fluorescence was then quenched by
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incubating 3 min in 1% sudan black followed by 5 quick dips in
PBS and 465 min PBS washes with shaking then mounting in
Prolong-Gold anti-fade reagent (Invitrogen).
Microscopy
Microscopy was performed using a Carl Ziss LSM 510 META
confocal microscope carrying lasers at 405, 488, 543 and 633 nm.
Images were captured using a 40 or 63X lens. LSM proprietary
software was used for digital image analysis. Images were
combined into figures for the manuscript using Adobe Photoshop
software. Images in Supplemental Figure S3 were taken with a
Olympus BX-60 (Olympus) equipped with epifluorescence optics,
digital camera (AxioCam MRm; Zeiss) and analyzed with Zeiss
Axiovision software.
Caspase assay
HEK 293 cells were used for the assay because of superior
transfection characteristics. Cells were grown in 10 cm plates,
transfected with TDP-43, trypsinized and plated in 96 well plates
using 10,000 cells/well. After 24 hrs, cells were treated with
vehicle or arsenite (150 mM or 50 mM). After 6 hrs or 12 hrs the
caspase assay was initiated by adding Caspase 3/7 Glo reagent
(Promega) and measuring after 45 min.
LDH assay
293-FT cells were transfected, and after 24 hrs the cells were
trypsinized, counted and plated on a 96 well plate at 10,000 cells/
well. The following day LDH release was measured using the Cyto
Tox 96 NonRadioactive Cytotoxicity Assay Kit (Promega) as per
manufacturers directions. Released LDH was normalized to total
LDH, and the results were further normalized to transfection
efficiency for each plasmid. LDH release from the EGFP
transfected cells was set as the baseline (100%).
Biochemical Fractionation
To examine the effect of arsenite on the solubility profiles of
wild type and mutant TDP-43, sequential protein extractions were
performed. 293FT Cells were washed twice with cold PBS, lysed in
cold RIPA buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 1%
NP-40, 0.1% SDS, 0.5 mM sodium deoxycholate) with 1x Halt
protease inhibitor cocktail (Thermo Scientific) and 1x phosphotase
inhibitor cocktail (PhosSTOP, Roche), and sonicated. Protein
concentrations were measured by BCA protein assay (Pierce).
Lysates were first centrifuged for 30 min at 100,0006g 4uC, and
the supernatants were collected as RIPA buffer soluble proteins.
To prevent contamination caused by carrying over, the pellets
were re-sonicated and re-centrifuged twice at 100,0006g for
30 min at 4uC. RIPA buffer-insoluble pellets were dissolved in
urea buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris-
HCl, pH 8.5) and sonicated. Soluble and insoluble proteins were
analyzed by western blot.
Immunoblot
Immunoblots were performed using gradient PAGE on a 15-
well, 4–20% Tris-Glycine gel (Invitrogen) as described previously
[48]. Antibody incubation was at 4uC overnight with rabbit
polyclonal TDP-43 antibody (1:1000, ProteinTech Group) or
mouse monoclonal actin antibody (1:5000, Millipore MAB1501)
in TBS-T plus 5% nonfat dry milk.
Immunoprecipitation
293FT cells were washed twice in cold phosphate-saline buffer
(PBS) and harvested by incubating with cold co-IP buffer (20 mM
Trish-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-
100, 1x Halt protease inhibitor cocktail (Thermo Scientific) and 1x
phosphotase inhibitor (PhosSTOP, Roche)) for 30 min on ice. The
protein concentrations were determined by BCA protein assay
(Pierce). Equal amounts of lysate were then treated with RNase A
(50 mg/ml) for 30 min at 37uC. Lysates were cleared by protein G
Dynabeads (Invitrogen) for 1 hour at 4uC; 1 ml of TDP-43
antibody (anti TDP-43 C-terminus 405–414, Cosmo Bio Co.) was
added to each cell lysate (300 mg) and the samples were incubated
for 3 hours at 4uC on a rotating wheel. 50 ml of protein G
Dynabeads was added to the samples, then the samples were
incubated for additional 1 hour at 4uC. The Dynabeads were
pulled down magnetically and washed three times in co-IP buffer.
Eluting buffer (Invitrogen) was added to the protein-bead
complexes to elute the binding proteins from the beads. The
eluted samples were boiled at 95uC for 5 min in SDS-sample
buffer. Proteins were then analyzed by western blot.
Protein Translation
HEK 293 cells were used (because of the superior transfection
efficiency over BE-M17 cells). Pulse labeling was done using the
manufacturer’s directions for the Click-iTHAHA protein metabolic
labeling kit (Invitrogen). Cells were incubated in methionine-free
medium for 1 hr, then transferred to fresh methionine-free medium
containing the azido-homoalanine reagent and incubated for 15 min,
then harvested. For studies using arsenite, cells were incubated in
methionine-free medium for 30 min, then arsenite was added and
incubation in methionine-free medium continued for another
30 min. Next, the cells were transferred to fresh medium containing
the azido-homoalanine reagent plus arsenite and incubated for
Table 1. Samples used for immunocytochemical studies of
TDP-43 in the human central nervous system.
ID Group
Tissue
Source Gender Age PMI
Cause of
Death
1 ALS Spinal Cord M 67 6 ALS
2 ALS Spinal Cord F 79 5 ALS
3 ALS Spinal Cord F 63 4 ALS
4 ALS Spinal Cord M 67 4 ALS
5 Control Spinal Cord F 58 5 Respiratory
Failure
6 Control Spinal Cord M 48 2 Hepatic Disease
7 Control Spinal Cord M 57 2 Pneumonia
8 Control Spinal Cord F 53 4 Pulmonary
Thrombosis
9 FTLD-U Frontal Cortex M 72 5 FTD
10 FTLD-U Frontal Cortex M 73 6 FTD
11 FTLD-U Frontal Cortex M 73 8 FTD
12 FTLD-U Frontal Cortex M 83 20 FTD
13 FTLD-U Frontal Cortex M 77 25 FTD
14 Control Frontal Cortex F 78 6 Myocardial
Infarction
15 Control Frontal Cortex F 87 4 Myocardial
Infarction
16 Control Frontal Cortex M 88 13 Lung Cancer
17 Control Frontal Cortex M 94 17 Heart Disease
18 Control Frontal Cortex F 87 24 Stroke
doi:10.1371/journal.pone.0013250.t001
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15 min, followed by harvesting and measurement of protein levels.
The azido-containing proteins were labeled with biotin as per
manufacturer’s directions. The resulting lysates were separated by
PAGE electrophoresis, blocked with 5% BSA and detected with
streptavidin-coupled horseradish peroxidase (1:40,000, 1 hr) followed
by enhanced chemiluminescence (Pierce) and exposure to film.
Tissue samples
All samples used in this study are described in Table 1. Cases of
ALS were obtained from the University of Pittsburgh Brain Bank
and the Center for ALS Research. Cases of FTLD-U were
obtained from the Boston University Alzheimer’s Disease Center
Brain Bank. Clinical diagnoses were made by board certified
neuropathologists according to consensus criteria for each disease.
Details on the cases are provided in the table below. Spinal cord
tissue was used for the studies of ALS and frontal cortex tissue was
used for the studies of FTLD-U. All tissues were paraffin
embedded. All human tissues were obtained through a process
that included written informed consent by the subjects’ next of kin.
The acquisition process was evaluated by the Institutional Review
Boards (Institutional Review Board of the Boston University
Medical Campus and the University of Pittsburgh Institutional
Review Board/University of Pittsburgh Committee for Oversight
of Research Involving the Dead) and determined to be exempt
from review by the full committee.
Supporting Information
Figure S1 Picture of the occasional cell expressing WT TDP-43
that has inclusions under basal conditions. The cells were labeled
with antibody against TIA-1 to test for co-localization with SGs.
Scale bar = 3 mm.
Found at: doi:10.1371/journal.pone.0013250.s001 (3.96 MB TIF)
Figure S2 Knockdown of TDP-43 does not affect SG formation.
A) Immunoblot of endogenous TDP-43 in HEK 293 cells
following knockdown with shRNA for TDP-43 or negative
control; HEK293 was used because of the high transfection
efficiency, which facilitates detection of changes by immunoblot.
B) Quantification of the number of cells per field with eIF3-
positive inclusions, using the experiment described in panel B. 30
fields were counted per condition.
Found at: doi:10.1371/journal.pone.0013250.s002 (1.27 MB TIF)
Figure S3 Pictures of human neuroblastoma BE-M17 cells
transfected with WT and mutant TDP-43. Cells were transfected
with the TDP-43-GFP constructs and then examined under three
conditions: basal, arsenite (0.5 mM, 1 hr) or arsenite plus
cycloheximide (50 mg/ml, 1 hr). The cells were labeled with
antibody against TIA-1 to test for co-localization with SGs. Scale
bar = 3 mm.
Found at: doi:10.1371/journal.pone.0013250.s003 (7.23 MB TIF)
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